Other Stories

Moderna reportedly pitches COVID-19 vaccine at US$ 50 to 60 per course Updated: 2020-07-29 17:05:15 KST

U.S.-based biotech company Moderna has reportedly pitched its COVID-19 vaccine at around 50 to 60 U.S. dollars per course.
The Financial Times reported that the price would apply to the U.S. and other high-income countries, though this is not likely to be final.
Currently, Moderna is in Phase 3 of its trial, enlisting 30-thousand participants across the U.S.
While Moderna has reportedly suggested a price of over 50 dollars for its vaccine, other developers, Pfizer and its partner BioNTech, last week agreed with the U.S. a price of 39 dollars per course or a little over 19 dollars per dose.

"They were priced at $19.50, which for a two-dose vaccine will be around a little bit less than $40. Less than what you would pay for many of the flu vaccines."

However, Pfizer said Tuesday that other developed countries would not be getting the vaccine at a lower price than what it charges the U.S.

On Tuesday alone, the U.S. added almost 16-hundred deaths, recording the highest daily total in over two months.
There were some 60-thousand new infections, with the total at over 4.3 million.
In addition, the White House has added three more states to its 'red zone' list,after reporting more than 100 new cases per 100-thousand people during the past week.
With Missouri, North Dakota and Wisconsin added, the total number of 'red zone' states is now 21.
The White House coronavirus task force recommends rolling back the reopening of economic and social activities in those states.
Yoon Jung-min, Arirang News.
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.